Purchase this article with an account.
Jonathan W Kowalski, Joanna Campbell, Gail F Schwartz, Britni LaBounty; Patient Adherence and Persistence with Topical Bimatoprost® 0.01% and Bimatoprost® 0.03%: an Analysis of Latanoprost Switchers. Invest. Ophthalmol. Vis. Sci. 2014;55(13):540.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare real-world adherence and persistence with bimatoprost 0.01% and bimatoprost 0.03% ophthalmic solutions in patients switching from branded latanoprost.
Patients receiving a first (index) prescription for bimatoprost 0.01% or 0.03% eye drops during April to June 2011 after previous treatment with branded latanoprost were identified from a longitudinal database (Source® Lx) of medical and pharmacy claims for >115 million patients. Treatment persistence was assessed over the first 12 months post-index using Kaplan-Meier survival analyses, assuming a 30-day grace period for prescription refill. The proportion of patients ‘on therapy’ (continuous users plus treatment restarters) was determined at 12 months. Treatment adherence was expressed as the proportion of days covered (PDC) with drug supply in the first 12 months, and as the proportion of patients with PDC >0.80. Sensitivity analyses explored the effects of varying the prescription refill gap.
In total, 2,464 patients were included in the persistence analysis and 2,037 patients were included in the adherence analysis. Significantly more patients showed continuous 12-month treatment with bimatoprost 0.01% vs bimatoprost 0.03% [39.8% (95% CI 37.5-42.2%) vs 23.8% (95% CI 20.8-27.3%), p<0.001]. At 12 months the proportion of patients ‘on therapy’ was significantly higher in the bimatoprost 0.01% than the bimatoprost 0.03% group (61.7% vs 42.6%, p<0.001). The persistence advantage with bimatoprost 0.01% vs 0.03% was maintained at refill gaps of 15-60 days. Adherence was significantly higher with bimatoprost 0.01% than with bimatoprost 0.03% (mean PDC 0.62 vs 0.51, p<0.001), and more patients showed optimal adherence (PDC > 0.80) with bimatoprost 0.01% than with bimatoprost 0.03% (38.6% vs 25.0%, p<0.001).
A previous pharmacy claims analysis reported greater adherence and persistence with bimatoprost 0.01% vs 0.03% in ocular hypertensive patients naïve to prostaglandin/prostamide analog therapy.1 This study supports and extends the previous research, demonstrating greater adherence and persistence with bimatoprost 0.01% than with bimatoprost 0.03% in patients switching from branded latanoprost. Sensitivity analyses using a range of refill gap assumptions support the robustness of the observed results. 1Campbell JH, et al. Curr Med Res Opin 2013; 29: 1201-1209
This PDF is available to Subscribers Only